SHOW DIRECTORY
Latent Space
Technical conversations for AI engineers and builders covering models, agents, developer tools, inference, data, and production infrastructure.
BIDCLUB DESCRIPTION
What Frontier Labs Buy: A Data Deep Dive with Handshake AI — Garrett Lord & Team
Garrett LordSahil BhaiwalaNishant RankaNick MagazineJonas MuellerCollin SchweikerSteve Kelling
A speaker projects the data market rising from $1 billion three years ago and $10 billion today to $100 billion three years from now.Longer tasks and wider professional coverage drive demand; expert-built environments and grading criteria can take days per example.A host reports few enterprises deploying end-to-end automation beyond copilots, making 2027 adoption a test of whether costly data reaches trusted workflows.
Mini Brains, Beating Heart Organoids, and the AI That Predicts Them — Fabian Theis, Helmholtz Munich
Ten million transcriptomes in one experiment and broader drug and CRISPR screens make virtual-cell modeling more actionable, though Theis says perturbation prediction is not the full ambition.The Cancer Organoid Perturbation Atlas offers a wedge: pharma partners pay for early access to distinctive datasets, while Lab Compass’s three or four feedback loops remain closer to active learning than reinforcement learning.
An Eval for AI Scientists That Knows the Answer Key - Ian Quigley, Leash Bio
Leash Bio makes agent decisions auditable across 90,000 rollouts, with 100-molecule budgets to find the best binder in a premeasured landscape.Astra 6 leads, and stronger models’ clearest edge is leaving poor chemical neighborhoods sooner, though why remains unknown.Leash plans to try for maybe 20 environments daily by early 2026 or 2027, but transfer to new biology remains unproven.
Why a 4-Billion-Point Kaggle Dataset Still Couldn’t Beat Chance — Ian Quigley, Leash Bio
Ian QuigleyBrandon AndersonRJ Honicky
Leash’s reported edge is low-cost, carefully characterized data: its ten-person operation developed about 2,000 protein constructs and ran roughly 5,000 screens.On the hardest Kaggle split, none of roughly 2,000 teams beat chance, exposing how poorly models transfer to distant chemistry.Language agents now test hypotheses instantly against measured compounds, but coverage remains limited and potency calibration unfinished.
Why AlphaFold Didn't Solve Protein Folding — Pushmeet Kohli, Google DeepMind & Sal Candido, Biohub
Pushmeet KohliSal CandidoBrandon Anderson
AlphaFold 2 reproduced PDB-deposited structures, but ground state, dynamics, function, and design remain open, shifting the frontier toward richer biological context and raw cryo-EM data.Metagenomic sequences show useful scaling depends on statistical fit rather than volume, while calibrated pLDDT and clearer bottlenecks—not a 10x or 100x timetable—determine whether AI can safely accelerate drug development.
🔬Bio-security is an AI Arms Race - Eric Nguyen (CEO, Radical Numerics)
Radical Numerics is positioning genome language models to move from reading DNA to designing functional sequences, with Omni’s post-training targeting variant effects in long-range, non-coding regions.The potential wedge is practical prediction across the roughly 98% of the human genome outside coding regions, while wet-lab validation, benchmark leakage, false positives, and biosecurity remain material execution risks.
🔬Biology Is Turning Into Software — Matt McPartland & Neil Patel, Chai Discovery
RJ HonickyMatt McPartlonNeil Patil
Chai Discovery is commercializing a neutral modeling and product layer for pharma rather than developing its own drugs, with partnerships including Eli Lilly, Pfizer, Novartis, and Genentech.Chai-2 designed antibodies against 50 targets, finding binders for about half with an average binding hit rate of around 20%, while enabling GPCR agonists and multispecific formats traditional screening struggles to produce.The opportunity depends on improving developability and epitope prediction, but compute scarcity, validation latency, and talent shortages remain structural constraints as Chai scales its platform.
🔬Causal Models Need Causal Data - Xaira’s X-Cell model (Bo Wang & Ci Chu)
Xaira links protein design, X-Cell, and patient-representation models around a causal drug-discovery loop, arguing that observational expression profiles cannot answer intervention questions.Seven genome-wide Perturb-seq campaigns across 16 contexts and 25 million filtered cells enabled X-Cell to transfer predictions from resting to activated T cells, held-out iPSC types, and primary donors, while patient, organ, and longitudinal dynamics remain unresolved.
🔬 RL with Verifiable Rewards, but the Verifier is a Lab — Lila Sciences
Andy BeamRafa Gómez-Bombarelli
Lila is betting that controlled experiments can become AI’s next internet-scale training corpus, with nature providing verifiable rewards and an information-gain-driven lab turning experiments into a compounding model moat.Lila reports a six-month, two- or three-person in vivo CAR-T program versus roughly six years and $100 million, but clinical translation, scale-up, regulation, and 5–6% model FLOPs utilization remain key watchpoints.
🔬 "The Most Innovative Diffusion Research Is Happening in Drug Discovery, Not Image Generation"
Brandon AndersonEvan FeinbergSergey Edunov
Genesis Molecular AI is applying diffusion and inference-time scaling to 3D molecular design, targeting roughly 1 Å protein-ligand accuracy because 2 Å can hide chemically fatal errors.Its prospective edge comes from Incyte and Insitro programs that connect models to synthesis and ADMET feedback, while OpenBind showed stronger unseen-target generalization and GPUs remain the scaling bottleneck.









